Abstract Endomorphin-1 (EM-1) and endomorphin-2 (EM-2) are two highly selective mu-opiate receptor agonists. We recently demonstrated that EM-1 and EM-2 have a saturable transport system from brain-to-blood in vivo. Since the endothelial cells are the main component of the non-fenestrated microvessels of the blood-brain barrier (BBB), we examined whether these endogenous tetrapeptides have a saturable transport system in cultured cerebral endothelial cells. EM-1 and EM-2 binding and transport were studied in a transwell system in which primary mouse endothelial cells were co-cultured with rat glioma cells. We found that binding of both endomorphins was greater on the basolateral than the apical cell surface. Flux of EM-1 and EM-2 occurred predominantly in the basolateral to apical direction, each showing self-inhibition with an excess of the respective endomorphin. Transport was not influenced by the addition of the Pglycoprotein inhibitor, cyclosporin A. Neither the muopiate receptor agonist DAMGO nor the delta-opiate receptor agonist DPDPE had any effect on the transport. Thus, the results show that a saturable transport system for EM-1 and EM-2 occurs at the level of endothelial cells of the BBB, and unlike ß-endorphin and morphine, Pglycoprotein is not needed for the brain-to-blood transport. Cross-inhibition of the transport of each endomorphin by the other suggests a shared transport system that is different from mu-or delta-opiate receptors. As endormorphins are mainly produced in the CNS, the presence of the efflux system at the BBB could play an important role in pain modulation and neuroendocrine control.
Introduction
The blood-brain barrier (BBB), formed by complex tightjunctions of the brain capillary endothelial cells, is an important regulatory system for maintaining the neural activity of the central nervous system (CNS). The BBB regulates transport of nutrients, hormones, and drugs between circulating blood and interstitial fluid.
Some peptides cross the BBB by saturable transport mechanisms while others cross by passive diffusion based on physicochemical properties (Davson and Segal 1996) . The first saturable transport system across the BBB to be shown for a peptide was for Tyr-MIF-1 (Tyr-Pro-Leu-Gly-NH 2 ) (Banks and Kastin 1984) . Endomorphin-1 (EM-1) and endomorphin-2 (EM-2), are two endogenous peptides selectively activating mu-opiate receptors (Zadina et al. 1997; Goldberg et al. 1998; Gong et al. 1998; Hosohata et al. 1998 ). The endormorphins are structurally similar to Tyr-MIF-1. We have shown in mice that the brain-to-blood efflux of EM-1 and EM-2 is a saturable process showing characteristics of self-inhibition and cross-inhibition . Although the P-glycoprotein transport system is responsible for the efflux of many therapeutic drugs out of the brain (Schinkel 1999; Terasaki and Hosoya 1999) , P-glycoprotein is not required for the brainto-blood transport of endomorphins in vivo (Kastin et al. 2002) .
Efflux systems usually serve to restrict entry or eliminate substrates from the brain (Schinkel et al. 1994; Kusuhara and Sugiyama 2001) . The physiological significance of the efflux system for endormorphins is not clear but probably is involved in pain modulation and neuroendocrine regulation. Endomorphins not only are potent analgesics but also can participate in immune modulation and behavioral changes (Bujdoso et al. 2001) , as do other ligands of mu-opiate receptors. The immunoreactivity of endomorphins in the brain and spinal cord under conditions of basal and neuropathic pain has been mapped in our laboratory and others (Martin-Schild et al. 1998 , 1999 Pierce et al. 1998; Smith et al. 2001; Wang et al. 2003a; b) .
Endomorphins have short half-lives in blood and brain, where they are rapidly degraded (Gentry et al. 1999; Hau et al. 2002 ). In the studies described here, therefore, we use isolated brain capillary endothelial cells as a model to further characterize the transport system for endomorphins at the BBB, including the kinetics of transport and the effects of potential inhibitors. The results will provide a basis for identification of the transporter in our future studies.
Materials and methods
Reagents EM-1and EM-2 were from American Peptide Company (Sunnyvale, CA, USA). Fetal bovine serum (FBS) was from Gibco (Rockville, MD, USA). DNase, L-1-chloro-3-7-amino-heptanone hydrochloride N-α-Tosyl-L-lysine chloromethyl ketone (TLCK), collagenase/ dispase were purchased from Roche Molecular Biochemicals (Indianapolis, IN, USA), and 8-(4-chlorophenylthio)-adenosine 3', 5'-cyclic monophosphate (CPT-cAMP) from Boehringer Mannheim (Indianapolis, IN, USA). Epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). RO-20-1724 was from Biomol Research Lab (Plymouth Meeting, PA, USA). DAMGO and DPDPE were from Multiple Peptide System (San Diego, CA, USA). The ABC Elite kit was obtained from Vector Laboratories (Burlingame, CA, USA). 125 INa was purchased from AmershamPharmacia, (Piscataway, NJ, USA). C6 rat glioma cells were obtained from American Type Culture Collection (Manassas, VA, USA). All other antibodies, chemicals and reagents were purchased from Sigma (St. Louis, MO, USA).
Iodination
EM-1 and EM-2 were labeled with 125 INa by chloramine-T and separated from unlabeled peptide by high performance liquid chromatography (HPLC). The peak effluent was dried in a speedvac, reconstituted in transport buffer, and frozen at −80°C in aliquots. The specific activities of both peptides were about 2,100 Ci/mmol. Human alpha-lactalbumin was labeled with 125 INa by chloramine-T and purified by Sephadex G10 column chromatography.
Cell cultures
Brain microvessel fragments were isolated from 20-25 g male ICR/ CD1 mice (Charles River, Wilmington, MA, USA) by the method of Abbot et al. (Abbott et al. 1992 ) with modifications. The mice were anesthetized with 40% urethane ip and used according to the NIH principles of laboratory animal care as approved by our Institutional Animal Care and Use Committee. After decapitation the neocortex was dissected into two hemispheres, the meningeal vessels were removed, and the tissue was transferred to buffer A (Hanks Balanced Salt Solution [HBSS] with 10 mM HEPES, 100 U/ml penicillin, 100 µg/ml streptomycin) with1% bovine serum albumin (BSA). The brain tissue was finely minced with a sterile blade and transferred to the homogenizing enzyme mix (collagenase/dispase 0.1%, DNase 20 U/ml, TLCK 0.147 µg/ml in buffer A), triturated with a pipette tip, and incubated 1 h at 37°C in a shaking water bath. Tissue pieces were separated from myelin by centrifugation in 25% BSA in buffer A, followed by a second digestion in the enzyme mix. Microvessels were separated from single cells and tissue fragments by centrifugation over a 50% Percoll gradient. The cells were applied to polyester transwell membranes (6.5 mm diameter, 0.4 µm pore size in 24 well plates; Corning, Corning, NY, USA), which were previously coated with 50 µg/ml rat tail collagen type I. At the same time, C6 rat glioma cells were plated on the bottom of the transwell system.
The microvessel fragments were cultured in a medium designed for microvascular endothelial cells (Dulbecco's Modified Eagle Medium [DMEM] supplemented with 15% FBS, 1 ng/ml bFGF, 1 µg/ml hydrocortisone, 10 ng/ml EGF) at 37°C in a humidified 5% CO 2 atmosphere with a change of medium every 2-3 days. In this polarized cell culture system, the basolateral side of the cells adhere to the collagen type I and the apical surface of the cells is apposed to the medium above. Therefore, the top (0.2 ml) of the transwell is called the luminal side and the bottom (1.0 ml), the abluminal side. At 70% confluence, the culture medium was supplemented with 250 µM CPT-cAMP and 17.5 µM of RO-20-1724 in order to get tight junction connections. Cell confluence was evaluated by measurement of transendothelial electrical resistance (TEER) across the cell monolayer with an Electrical Resistance System (World Precision Instruments, Sarasota, FL, USA). TEER was calculated as total resistance − cell free (blank) resistance. Binding and transport assays were performed when a consistent electrical resistance of 80-100 ohms [26.5-33 ] total) was obtained, usually between days 9 and 12 after plating the cells into the transwell system.
Immunocytochemistry
Brain microvessel cells cultured on the transwell system were washed three times with phosphate-buffered saline (PBS) and fixed in 4% paraformaldehyde. Endogenous peroxidase activity was blocked with 0.5% H 2 O 2 for 1 h at room temperature, and the membranes were washed in PBS, treated with normal sera, and incubated with anti-factor VIII-related antigen (specific for endothelial cells) or anti-GFAP (specific for astrocytes) overnight at 4°C. After several washes in PBS, the cells were incubated with a biotinylated second antibody at room temperature. The immunochemical detection was visualized with Vectastain Elite ABC kit and DAB substrate kit for peroxidase, according to the manufacturer's instructions.
Transport assays
Primary brain microendothelial cells (PBMEC) were plated in triplicate at a starting density of 2×10 5 /ml cells onto the transwell system, and C6 cells were plated at a density of 10 5 /ml cell on the bottom of the wells. After reaching confluence and high electrical resistance, the transwell membranes were moved to C6 cells-free wells, washed with transport buffer (DMEM + 0.1% BSA), and incubated for 30 min at 37°C with 5% CO 2 . For apical to basolateral experiments, at time zero, the media was removed from the luminal side and replaced with 200 µl transport buffer containing 125 I-EM-1, 125 I-EM-2 or 125 I-lactalbumin (10 6 cpm/0.2 ml). The abluminal side contained 1 ml of transport buffer. For basolateral to apical experiments, the labeled material was added to the abluminal side in 1 ml transport buffer, and the luminal side contained the transport buffer only. In some cases, the compounds of interest (unlabeled EM-1 and EM-2, DAMGO, DPDPE, or cyclosporin A) were mixed with the labeled peptides before addition to the wells.
The plates were incubated at 37°C with shaking. At 5, 10, 15, 20, 30, 45 and 60 min, 10 µl of sample was taken from the abluminal side (for apical transport) or from the luminal side (for basolateral transport) for analysis of radioactivity and immediately replaced with 10 µl transport buffer to maintain the same buffer volume throughout the experiment.
For the apical to basolateral experiments, the percent material transported at each time point was defined as [0.5 × cpm counted in the 10 µl sample taken from the abluminal side/all the cpm added to the luminal side] × 100. For the basolateral to apical experiments, the percent material transported at each time point was calculated as [0.05 × cpm counted in the 10 µl sample taken from the luminal side/all cpm added to the abluminal side] × 100. The percent of transported material was plotted against time, and the regression lines were determined by the least-squares method.
Binding assays
To assess 125 I-EM-1 or 125 I-EM-2 binding on the apical or basolateral cell surface, binding assays were carried out with either 125 I-EM-1 or 125 I-EM-2 and PBMEC culture. Binding of 125 I-EM-1 or 125 I-EM-2 was done at 4°C in transport buffer (DMEM + 0.1% BSA) to minimize endocytosis and intracellular processing of the hormones. Cells were washed three times in ice-cold transport buffer and then incubated with 10 5 cpm/ml labeled peptide added either to the apical or the basolateral chamber for 4 h. To differentiate bound cpm from nonspecific background binding, binding of the labeled peptide was carried out in the presence or absence of excess unlabeled EM-1 or EM-2 (1 µg/ml). After incubation, the membranes were washed three times with ice-cold transport buffer, cut from the transwell with a scalpel, and counted in a γ-counter. The number of cpm bound above the background was defined as: [total cpm bound − cpm bound in the presence of cold peptide].
Degradation analysis
To determine the degree to which transported cpm represented intact EM-1 or EM-2, trichloroacetic acid (TCA) precipitation was carried out on media collected from chambers contralateral to that to which radiolabeled ligand was added. At the end of the transport experiment, 100 µl of media were collected from each chamber and mixed with 1 ml 30% TCA dissolved in brine NaCl. After incubation for 5 min at room temperature, the tubes were centrifuged at 1,500 g for 10 min at 4°C. The supernatant was decanted to another tube and both tubes measured in a γ-counter. The percent of intact peptide was calculated as: [cpm pellet / cpm pellet + supernatant] × 100. Controls consisted of samples taken from the radiolabeled stock. To further verify that intact EM-1 or EM-2 were present in the transported media, 10 4 cpm in 100 µl media was injected onto a C18 column and separated by HPLC. The percentage of the peak effluent was compared with the control, intact radiolabeled stock.
Statistical analysis
Groups were compared by analysis of variance (ANOVA) followed by Newman-Keuls's multiple comparison tests. Regression lines were determined by the least-squares method and the differences between slopes compared by GraphPad Prism statistical software (GraphPad Software, San Diego, CA, USA).
Results

Cell culture
The mouse brain microvessel fragments became attached to the collagen-coated transwell membrane within 24 h and spread slowly onto the surface over the first week, becoming a confluent monolayer by 9-13 days of culture. At days 7-9, the medium was supplemented with CPTcAMP (a cell membrane-permeable cAMP analogue) and RO-20-1740 (a phospohodiesterase inhibitor) in order to get tight junctions on the monolayer, which increased the TEER across the PBMEC+C6 glioma co-culture (Fig. 1) . The electrical resistance measured reached a plateau between days 9 and 12, when the resistance was 95-98 ± 4 ohms [31.5-32.5 ± 1.3 ohmscm 2 ]. After day 13, the TEER started to decline and the variance became larger among the wells (80±6.2 ohms [26.5±2.1 ohmscm 2 ]). Based on the TEER measurements, which correspond with the permeability of the monolayer and the light microscopic appearance of the endothelial cells, we decided to do the experiments between days 9 and 12, when the TEER was the highest and the cells were confluent.
Immunocytochemistry
The immunocytochemical analysis of representative cultures with an endothelial cell-specific marker (factor VIII-related antigen) showed that about 95% of the cells were endothelial. Very few, if any, cells were stained with anti-GFAP, indicating a pure endothelial cell culture. Figure 2 shows that the transport of 125 I-EM-1 and 125 I-EM-2 is unidirectional, from basolateral to apical surface. The K i of 125 I-EM-1 is 0.0359±0.0014%/min from apical to basolateral (influx) and 0.1248±0.072%/min from basolateral to apical sides (efflux).
Transport assays
125
I-EM-2 showed a similar pattern, with a K i of 0.0341±0.0017%/min from apical to basolateral and 0.0997±0.003%/min from basolateral to apical sides.
I-lactalbumin showed a slow influx and efflux rate of 0.0378±0.0026%/min and 0.0339 ±0.0024%/min, respectively, which is significantly The addition of unlabeled, excess EM-1 or EM-2 decreased the efflux rate of 125 I-EM-1 (Fig. 3 ) significantly (p<0.001), resulting in a K i of 0.087±0.0048%/min in the presence of an excess of 100 ng/ml EM-1, 0.068 ±0.0036%/min with 1,000 ng/ml EM-1 (p<0.01 between the two doses), 0.08±0.0025%/min with 100 ng/ml EM-2, and 0.074±0.0059%/min with 1,000 ng/ml EM-2 (no significant change between doses).
The efflux rate of 125 I-EM-2 also was reduced by the addition of each of the unlabeled peptides to the labeled material (Fig. 4) . The K i was reduced from 0.0997±0.03%/ min to 0.092±0.0024%/min by the addition of 100 ng/ml Fig. 2 Comparison of 125 I-EM-1, 125 I-EM-2, and 125 I-lactalbumin transport from the apical to basolateral (A to B) and from the basolateral to apical (B to A) side. There was a significant efflux of both endomorphins compared with the efflux rate of lactalbumin (p<0.001). Each data point represents the mean ± SEM of three determinations in triplicate Fig. 4 Transport of 125 I-EM-2 and 125 I-lactalbumin from the basolateral to apical side in mouse endothelial cells grown on collagen-coated transwell. In some experiments, unlabeled EM-1 or EM-2 (100 ng/ml or 1,000 ng/ml) was added to the transport buffer. This resulted in self-inhibition characteristic of a saturable system. P<0.001 for the addition of 1,000 ng/ml EM-1 or EM-2. The inclusion of 100 ng/ml EM-1 or EM-2 resulted in a nonsignificant change of transport. Each data point represents the mean ± SEM of three determinations Fig. 5A , B The presence of 0.1 or 1 µM of cyclosporine A, a Pglycoprotein inhibitor, did not change the efflux of 125 I-EM-1 (A) or 125 I-EM-2 (B) on cultured endothelial cells. Each data point represents the mean ± SEM of three determinations Fig. 3 Transport of 125 I-EM-1 and 125 I-lactalbumin from the basolateral to apical direction on mouse endothelial cells grown on collagen-coated transwell. In some experiments, unlabeled EM-1 or EM-2 (100 ng/ml or 1,000 ng/ml) was added to the transport buffer. This resulted in significant self-inhibition characteristic of a saturable system. Each data point represents the mean ± SEM of three determinations EM-2, a nonsignificant change, while the inclusion of 1,000 ng/ml EM-2 resulted in a significant (p<0.001) decrease of the efflux rate (0.078±0.0069%/min).
The addition of unlabeled, excess EM-1 to the 125 I-EM-2 containing transport media caused similar changes. There was a nonsignificant change of the efflux rate with the addition of 100 ng/ml EM-1 (0.1048±0.0054%/min). However, 1,000 ng/ml cold EM-1 decreased the efflux (0.064±0.0051%/min) of 125 I-EM-2 significantly (p<0.001).
In the next experiments, we added excess cyclosporin A (a P-glycoprotein inhibitor) to the labeled peptides to determine whether the transport was mediated by the Pglycoprotein system. The doses chosen, 0.1 or 1 µM, are known to inhibit the P-glycoprotein system without affecting the TEER (van der Sandt et al. 2001 ). The inclusion of cyclosporin A to 125 I-EM-1 or 125 I-EM-2 containing media did not change the efflux of either peptides (Fig. 5A, B) .
Neither the mu-opiate receptor agonist DAMGO nor the delta-opiate receptor agonist DPDPE had a significant effect on the transport of either EM-1 or EM-2 (Fig. 6A,  B) .
Binding assays
Because PBMEC cells exhibit differentiated plasma membranes when grown on the substrate, we next tested whether the binding of 125 I-EM1 or 125 I-EM-2 might be polarized to either the apical or basolateral cell surface. By measuring binding to PMBEC at 4°C, we found that both labeled peptides showed significantly higher binding to the basolateral surface compared with the apical surface (Fig. 7) .
125 I-EM-1 bound to the basolateral surface eight times higher than to the apical side, while 125 I-EM-2 showed six times higher binding to the basolateral side than to the apical.
Degradation analysis
To determine the amount of transported radioactivity, which represented intact EM-1 or EM-2, we first Fig. 6A , B The addition of 100 ng/ml or 1,000 ng/ml of the muopiate receptor agonist DAMGO or the delta-opiate receptor agonist DPDPE to the 125 I-EM-1 (A) or 125 I-EM-2 (B) containing media did not result in a significant change in the efflux rate of these peptides. Each data point represents the mean ± SEM of three determinations I-EM-2 was added to either the apical or the basolateral chamber for 4 h at 4°C. Cells were then washed and counted in a γ-counter. Values represent the mean ± SEM of three measurements performed TCA precipitation on media taken from the basolateral or apical chamber at the end of the experiments (60 min). We found that 84±3.6% of the transported EM-1 and 81±4.5% of the transported EM-2 were precipitated by TCA. Almost all (95±0.8% for EM-1 and 93±2.1% for EM-2) of the radioactivity in the stock 125 I-EM-1and 125 I-EM-2 was precipitated by TCA.
Media taken from the basolateral or apical chamber of the transwell system at 60 min was then subjected to HPLC analysis. It showed that 76±4.3% and 71±3.5% of the radioactivity recovered represented intact 125 I-EM-1 and 125 I-EM-2, respectively. The groups receiving the labeled peptides and various concentrations of unlabeled EM-1 or EM-2 did not have a significant decrease in the percent of intact 125 I-EM-1 and 125 I-EM-2, showing that addition of excess cold peptides did not influence the rate of degradation.
Discussion
We have established a primary mouse brain endothelial culture system on membranes that serves as a model of the in vitro BBB. This system was used for assessment in vitro of the transport of EM-1 and EM-2. Immunohistochemical staining showed that the culture system consisted of pure endothelial cells. In vitro models are generally more permeable than the BBB in vivo, but permeability can be decreased by co-culturing the cells with astrocytes (Rubin et al. 1991) or by the use of various compounds that cause an elevation of cAMP levels, thereby increasing barrier function (Rubin and Staddon 1999) . With these approaches, we were able to obtain relatively high TEER. The lack of lactalbumin transport and the significantly different transport of endomorphins across the cells in the abluminal to luminal direction as compared with the opposite direction established the functionality of the system.
Our results show that EM-1 and EM-2 have a saturable efflux system. This was established by self-inhibition of the transport of each radioactively labeled peptide by an excess of the corresponding peptide. There also was crossinhibition of the rate of efflux of each endomorphin by the other: the excess of EM-2 inhibited the efflux of EM-1, and an excess of EM-1 inhibited the efflux of EM-2. This indicates shared components for the brain-to-blood transport of these peptides. These findings are consistent with our in vivo results .
Several investigators have shown that the P-glycoprotein transport system is responsible for the efflux of many therapeutic drugs out of the brain (Schinkel 1999; Terasaki and Hosoya 1999) . However, in our in vitro experiments, the rates of efflux of EM-1 and EM-2 were not influenced by cyclosporin A, a P-glycoprotein inhibitor, indicating that, in contrast to endorphin (King et al. 2001) , the endomorphins do not require P-glycoprotein for transport out of the brain. This supports our previous in vivo finding (Kastin et al. 2002 ) of a saturable efflux system for endomorphins in P-glycoprotein knockout mice. However, this is in contrast with the findings of Oude Elferink and Zadina (2001) who showed that P-glycoprotein transports endogenous opiate peptides including EM-1 and EM-2. This discrepancy from our results might be explained by different in vitro systems. They used a transfected nonsmall cell lung cancer cell line SW1573/SI, while our system consists of primary brain microvessels, which is more closely related to the BBB in vivo.
The addition of the mu-opiate receptor agonist DAMGO, or the delta-opiate receptor agonist DPDPE, had no effect on the efflux of either peptide, indicating no involvement of these receptors in the transport. Similar results were found on crude microvessel preparations, where DAMGO, DPDPE and the kappa-opiate receptor agonist U50488 did not change 125 I-Tyr-MIF-1 binding (Maresh et al. 1999) . Thus, the transporter of EM-1 and EM-2 is different from its binding protein, the mu-opiate receptor.
The P-glycoprotein transporter system is expressed on brain capillaries and localized on the luminal membrane (Cordon-Cardo et al. 1989) . Multidrug resistance-associated proteins (MRPs), transporting conjugated metabolites such as glutathione-and glucuronide-conjugates (Loe et al. 1996; Kusuhara et al. 1998) , are expressed and localized on the basal membrane of testis Sertolli cells and the basolateral membrane of lung epithelial cells (Wijnholds et al. 1998; Wright et al. 1998 ) but no expression of MRPs was detected on isolated human brain capillaries (Seetharaman et al. 1998) and no significant staining was found in mouse brain (Wijnholds et al. 2000) . Breast Cancer Related Protein (BCRP) is located at the BBB, mainly at the luminal surface of microvessel endothelium (Cooray et al. 2002) . The preferential binding of EM-1 and EM-2 on the basolateral membrane in our polarized cell model suggests an efflux transporter located on the abluminal side of the BBB. However, it is possible that other efflux systems may share transport capabilities with the endomorphin system. In summary we have shown that (1) EM-1 and EM-2 have a unidirectional transport in vitro; (2) the transport is saturable, as shown by the inhibition of transport of trace amounts of these peptides by an excess of the corresponding peptide; (3) EM-1 and EM-2 have shared transport, indicated by cross-inhibition of the rate of efflux of each endomorphin by the other; (4) the P-glycoprotein transport system is not involved because the addition of a Pglycoprotein inhibitor did not change the transport; (5) the transporter is not related to the mu-or delta-opiate receptors because agonists for these receptors do not inhibit transport; and (6) the brain-to blood transporter of EM-1 and EM-2 may represent a different type of mechanism in which basolateral binding is a rate-limiting step in the efflux.
